Mark Rothera - 19 Sep 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: President and CEO, Director
Signature: /s/ Daniel Chevallard, as Attorney-in-Fact
Issuer symbol: VIRX
Transactions as of: 19 Sep 2022
Net transactions value: $0
Form type: 4
Filing time: 19 Sep 2022, 19:04:44 UTC
Next filing: 17 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+1,375,000		$0.000000	1,375,000	19 Sep 2022	Common Stock	1,375,000	$5.21	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the grant date and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, the last day of the month), subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date.

Content

Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the grant date and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, the last day of the month), subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date.